Jee Woo Kim

Jee Woo Kim

Auto-generated profile, based on publicly available information

Jee Woo Kim

Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MKM.J. Kim
M.J. Kim
JKJee Woo Kim
Jee Woo Kim
MKM.S. Kim
M.S. Kim
SCSun Young Choi
Sun Young Choi
JNJung-Im Na
Jung-Im Na
Since the outbreak of COVID-19 in December 2019, more than 4 million people have died worldwide. The global pandemic of COVID-19 has prompted each country to issue an emergency use authorization for COVID-19 vaccines. In South Korea, the Ministry of Food and Drug Safety authorized the administration of four vaccines; Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), Oxford–AstraZeneca (ChAdOx1), and Johnson & Johnson’s Janssen (JNJ-78436735). Although these vaccines were presumed to be safe, several nonspecific skin eruptions have been reported after the health system initiated public COVID-19 vaccination1. Here, we report a patient who developed de novo erythema multiforme (EM) following COVID-19 vaccination with BNT162b2.

27 March 2023 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
BKBo Ri Kim
Bo Ri Kim
SWSeung Hyun Won
Seung Hyun Won
JKJee Woo Kim
Jee Woo Kim
MKMinjae Kim
Minjae Kim
JJJeong-Il Jeong
Jeong-Il Jeong
JNJung-Im Na
Jung-Im Na
There has been no validated tool for objectively quantifying the overall condition and characteristics of the scalp. This study aimed to establish and validate a new classification and scoring syst...


19 May 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
JKJee‐Woo Kim
Jee‐Woo Kim
CHChang‐Hun Huh
Chang‐Hun Huh
JNJung‐Im Na
Jung‐Im Na
JHJoon‐Seok Hong
Joon‐Seok Hong
JPJee Yoon Park
Jee Yoon Park
JSJung-Won Shin
Jung-Won Shin

5 May 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
MKMinsu Kim
Minsu Kim
MKMinjae Kim
Minjae Kim
JKJee‐Woo Kim
Jee‐Woo Kim
BKBo Ri Kim
Bo Ri Kim
SYSang Woong Youn
Sang Woong Youn

17 June 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MKMinsu Kim
Minsu Kim
JKJee-Woo Kim
Jee-Woo Kim
JSJung-Won Shin
Jung-Won Shin
JNJung-Im Na
Jung-Im Na
Chang-Hun HuhChang-Hun Huh
Chang-Hun Huh
Basal cell carcinoma (BCC) affecting different sites has been reported to have different clinicopathological features. In previous studies, the scalp was commonly classified to the head and neck region. However, the scalp has distinct characteristics from those of other parts of the skin. We retrospectively reviewed the medical records of patients who underwent surgical treatment for BCC. A total of 734 lesions were examined, and 13.2% originated from the scalp. The nodular type was the most common histologic subtype; however, the proportion of the superficial type was significantly higher than that of facial BCC (p < 0.001). Compared with facial BCC, younger age (p = 0.046) and larger tumor size (p < 0.001) were observed in scalp BCC. These characteristics were similar to those of truncal BCC in that they demonstrated a higher proportion of the superficial type (p < 0.001), younger age (p = 0.001), and larger tumor diameter (p < 0.001) compared with BCC in the head and neck region. Scalp BCC and truncal BCC were not significantly different in terms of age (p = 0.052) and tumor size (p = 0.230). In conclusion, despite the anatomical proximity, features of scalp BCC were similar to those of truncal lesions compared with facial lesions. Scalp BCC might be a separate entity from facial BCC.